Efemia was launched in the UK in late 2019 together with the distributor Advanced Global Health (AGH). Users as well as healthcare entities in the UK have shown a strong interest in Efemia, and the agreement with NHS England constitutes the next important step as physicians, specialised nurses and pelvic floor therapists will be able to prescribe the product to their patients. The agreement is for England and thus covers a large majority of all women in the UK.

"It is satisfying that Efemia has been approved for prescription with cost coverage in this large and influential European market encompassing almost 7 million women with stress urinary incontinence (SUI). This agreement with NHS England makes the product much more available for women in need of a simple, effective and non-surgical solution for SUI, and they do not have to worry about the cost, says Invent Medic’s CEO Karin Bryder.

"Our team is incredibly happy to announce that Efemia bladder support is now available on NHS Prescription. We are proud that we can continue to make available life changing and innovative products to as many women as possible. Offering a reusable, clinically proven and comfortable alternative to pads and older style vaginal inserts is a major step forward for women who may suffer with SUI," says Alexander Fisher, CEO of Invent Medic’s British distributor AGH.

In addition to England, Efemia has already been approved for prescription with cost coverage in Norway and the Netherlands, and the product can also be prescribed in five Swedish regions and 21 municipalities in Denmark.

For more information please contact
Karin Bryder, CEO
Phone: +46 (0)723811710
E-mail: info@inventmedic.com 

About Invent Medic
Invent Medic Sweden AB (Invent Medic) is a Swedish company developing innovative products with the aim to improve women’s health and quality of life. The company’s products are to be safe, effective and easy to use. Invent Medic’s first product, Efemia, is a CE-certified and patented medical technology product used to reduce stress urinary incontinence (SUI) that was shown to reduce urine leakage with 77 percent during usage in a clinical study. The product is based on the same scientific principle as the TVT method, the premier surgical treatment for SUI. Invent Medic’s share is listed on the Spotlight Stock Market with the ticker symbol IMS, and the share’s ISIN code is SE0007603402. More information can be found at www.inventmedic.com and www.spotlightstockmarket.com.